Compare Menicon Co., Ltd. with Similar Stocks
Dashboard
1
High Management Efficiency with a high ROCE of 12.03%
2
Company's ability to service its debt is strong with a healthy EBIT to Interest (avg) ratio of 22.66
3
With a growth in Net Profit of 47.83%, the company declared Very Positive results in Dec 25
4
With ROCE of 8.92%, it has a very attractive valuation with a 0.93 Enterprise value to Capital Employed
5
Underperformed the market in the last 1 year
Stock DNA
Pharmaceuticals & Biotechnology
JPY 123,579 Million (Small Cap)
12.00
NA
0.00%
0.41
6.04%
1.43
Revenue and Profits:
Net Sales:
32,452 Million
(Quarterly Results - Dec 2025)
Net Profit:
3,197 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
8.56%
0%
8.56%
6 Months
47.7%
0%
47.7%
1 Year
28.89%
0%
28.89%
2 Years
2.75%
0%
2.75%
3 Years
-37.8%
0%
-37.8%
4 Years
-42.2%
0%
-42.2%
5 Years
-44.54%
0%
-44.54%
Menicon Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
7.53%
EBIT Growth (5y)
7.40%
EBIT to Interest (avg)
22.66
Debt to EBITDA (avg)
0.65
Net Debt to Equity (avg)
0.31
Sales to Capital Employed (avg)
0.77
Tax Ratio
39.68%
Dividend Payout Ratio
37.83%
Pledged Shares
0
Institutional Holding
0.22%
ROCE (avg)
12.03%
ROE (avg)
8.66%
Valuation key factors
Factor
Value
P/E Ratio
12
Industry P/E
Price to Book Value
0.91
EV to EBIT
10.47
EV to EBITDA
5.69
EV to Capital Employed
0.93
EV to Sales
0.87
PEG Ratio
1.04
Dividend Yield
NA
ROCE (Latest)
8.92%
ROE (Latest)
7.35%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Mildly Bullish
Dow Theory
Mildly Bearish
No Trend
OBV
No Trend
Mildly Bullish
Shareholding Snapshot : Jun 2024
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 1 Foreign Institutions (0.22%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ
Dec'25
Sep'25
Change(%)
Net Sales
32,452.00
31,229.00
3.92%
Operating Profit (PBDIT) excl Other Income
6,513.00
5,641.00
15.46%
Interest
206.00
205.00
0.49%
Exceptional Items
0.00
0.00
Consolidate Net Profit
3,197.00
2,162.00
47.87%
Operating Profit Margin (Excl OI)
118.10%
102.70%
1.54%
USD in Million.
Net Sales
QoQ Growth in quarter ended Dec 2025 is 3.92% vs 3.23% in Sep 2025
Consolidated Net Profit
QoQ Growth in quarter ended Dec 2025 is 47.87% vs 117.94% in Sep 2025
Annual Results Snapshot (Consolidated) - Mar'25
Mar'25
Mar'24
Change(%)
Net Sales
121,491.00
116,192.00
4.56%
Operating Profit (PBDIT) excl Other Income
18,502.00
16,900.00
9.48%
Interest
751.00
672.00
11.76%
Exceptional Items
-175.00
-1,112.00
84.26%
Consolidate Net Profit
5,624.00
4,541.00
23.85%
Operating Profit Margin (Excl OI)
82.70%
77.10%
0.56%
USD in Million.
Net Sales
YoY Growth in year ended Mar 2025 is 4.56% vs 5.44% in Mar 2024
Consolidated Net Profit
YoY Growth in year ended Mar 2025 is 23.85% vs -38.47% in Mar 2024
About Menicon Co., Ltd. 
Menicon Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






